- Home
- VSTM vs NGNE Comparison
VSTM vs NGNE Comparison
Compare VSTM & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | NGNE |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.8M | 744.9M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VSTM | NGNE |
|---|---|---|
| Price | $7.54 | $37.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $16.50 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 2.0M | 195.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $282.64 | N/A |
| Revenue Next Year | $72.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $3.43 | $15.93 |
| 52 Week High | $10.82 | $43.66 |
Technical Indicators
Market Signals| Indicator | VSTM | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 49.91 |
| Support Level | $6.68 | $35.26 |
| Resistance Level | $7.86 | $42.84 |
| Average True Range (ATR) | 0.39 | 2.48 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 48.70 | 27.85 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.